Sickle cell disease causes accelerated kidney function decline, yet proven GFR-preserving therapies remain elusive. In this study of adults with sickle cell disease, RASi use was not associated with a significant difference in the rate of eGFR decline.
More episodes from "Kidney360"



Don't miss an episode of “Kidney360” and subscribe to it in the GetPodcast app.








